Argentina Hemato Oncology Testing Market Size & Outlook

The hemato oncology testing market in Argentina is expected to reach a projected revenue of US$ 70.9 million by 2028. A compound annual growth rate of 13.4% is expected of Argentina hemato oncology testing market from 2021 to 2028.
Revenue, 2020 (US$M)
$25.9
Forecast, 2028 (US$M)
$70.9
CAGR, 2021 - 2028
13.4%
Report Coverage
Argentina

Argentina hemato oncology testing market highlights

  • The Argentina hemato oncology testing market generated a revenue of USD 25.9 million in 2020 and is expected to reach USD 70.9 million by 2028.
  • The Argentina market is expected to grow at a CAGR of 13.4% from 2021 to 2028.
  • In terms of segment, lymphoma was the largest revenue generating cancer type in 2020.
  • Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.


Hemato oncology testing market data book summary

Market revenue in 2020USD 25.9 million
Market revenue in 2028USD 70.9 million
Growth rate13.4% (CAGR from 2020 to 2028)
Largest segmentLymphoma
Fastest growing segmentLymphoma
Historical data2018 - 2019
Base year2020
Forecast period2021 - 2028
Quantitative unitsRevenue in USD million
Market segmentationLeukemia, Lymphoma, MPNs, Other Cancers
Key market players worldwideRoche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp


Other key industry trends

  • In terms of revenue, Argentina accounted for 1.1% of the global hemato oncology testing market in 2020.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
  • In Latin America, Brazil hemato oncology testing market is projected to lead the regional market in terms of revenue in 2028.
  • Mexico is the fastest growing regional market in Latin America and is projected to reach USD 165.6 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemato Oncology Testing Market Companies

Name Profile # Employees HQ Website

Argentina hemato oncology testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.


Lymphoma was the largest segment with a revenue share of 45.95% in 2020. Horizon Databook has segmented the Argentina hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.


According to Globocan estimates, in 2020 around 3,557 new cases of non-Hodgkin lymphoma and 3,234 new cases of leukemia were identified in Argentina. Such high incidence of the disease is expected to drive the demand for testing solutions in the country.

Furthermore, initiatives by several nonprofit organizations such as Lymphomas Argentina, a member of the Lymphoma Coalition supporting the patients with lymphoma, leukemia and related diseases is expected to increase awareness about the early diagnosis of disease and support the market growth.

Reasons to subscribe to Argentina hemato oncology testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Argentina hemato oncology testing market databook

  • Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Argentina hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into Argentina hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Argentina hemato oncology testing market size, by cancer type, 2018-2028 (US$M)

Argentina Hemato Oncology Testing Market Outlook Share, 2020 & 2028 (US$M)

Argentina hemato oncology testing market size, by cancer type, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more